SIRPA and osteosarcoma: Although there are limited studies on anti-CD47/SIRPα therapy in osteosarcoma, these suggested strategies targeting CD47/SIRP-α that turn the ‘don’t eat me’ signal off may be an efficient therapy in osteosarcoma.